drugset / Trial / NCT05401786
Anti-PD-1 Re-challenge After Immune Priming by Ipilimumab and Immune Boosting by Radiotherapy in Advanced NSCLC
Phase 2
Active not recruiting
54 enrolled
The Netherlands Cancer Institute
Genzyme, a Sanofi Company · collab
NaSingle-groupOpen-labelTreatment
Summary
Still many advanced non-small cell lung cancer (NSCLC) patients do not benefit from PD-(L)1 inhibition or will eventually develop progression through secondary resistance. Inhibition of CTLA-4, application of radiotherapy together with PD-1 inhibition showed synergistic effects and is deemed safe.
Timeline
- Start
- 2023-01-03
- Primary completion
- 2024-11-15
- Completion
- 2026-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cemiplimab | Monoclonal antibody | 350 mg | Intravenous |
| Subject | Ipilimumab | Monoclonal antibody | 1 mg/kg | Intravenous |